TrialClinical and translational science2025

A First-in-Human, Single- and Multiple-Dose Study of APG777, a Half-Life-Extended Anti-IL-13 Monoclonal Antibody, in Healthy Volunteers.

Xiu Qin Lim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.